GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2008

Quintessence Retains Althea Technologies to Produce First Lead Candidate

  • Althea Technologies was awarded a contract from Quintessence Biosciences under a manufacturing supply agreement to produce the firm’s first drug candidate.

    QBI-139 is effective in cancer models against a broad range of solid tumors, according to Quintessence. The company plans to file an IND for QBI-139 in the first quarter. Althea will provide protein production, purification, and aseptic filling services to produce the clinical trial materials.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?